Related Experiment Video
Updated: Jan 7, 2026
08:37
Assessment of Glutamine as a Fuel Source for Alveolar Macrophages Exposed to Chronic Ethanol Using an Extracellular Flux Bioanalyzer
Published on: November 15, 2024
702
Metabolic dysfunction and alcohol-associated liver disease (MetALD)
Bin Gao1, Juan Pablo Arab2, Suthat Liangpunsakul3
1Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland, USA.
Egastroenterology
|December 29, 2025
Summary
Metabolic dysfunction and alcohol-associated liver disease (MetALD) combines metabolic issues with alcohol consumption. Understanding MetALD is crucial for managing liver disease in at-risk individuals.
Area of Science:
- Hepatology
- Metabolic Disorders
- Alcohol-Related Diseases
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) patients consuming significant alcohol are now termed MetALD.
- MetALD diagnosis requires metabolic risk factors and specific alcohol intake levels (women: 140–350 g/week; men: 210–420 g/week).
- Distinct from traditional alcohol-associated liver disease (ALD) with higher consumption thresholds.
Purpose of the Study:
- To review the current definition, diagnosis, and management of MetALD.
- To explore emerging insights into MetALD pathogenesis.
- To discuss experimental models and future research directions.
Main Methods:
- Comprehensive literature review.
- Synthesis of current diagnostic criteria and clinical management strategies.
- Examination of experimental models and pathogenesis research.
Main Results:
- MetALD is a heterogeneous condition influenced by metabolic profiles, drinking patterns, and susceptibility.
- Alcohol and metabolic factors synergistically accelerate liver injury, including steatohepatitis, fibrosis, and cancer.
- Precise mechanisms of liver injury in MetALD require further elucidation.
Conclusions:
- MetALD represents a significant clinical challenge requiring a better understanding of its complex mechanisms.
- Further research is needed to refine diagnostic criteria and therapeutic strategies.
- Identifying research priorities is essential for advancing the field of MetALD.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
165
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
165
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
197
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
197
01:20Inborn Errors of Metabolism
679
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
679
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
182
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
182
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
153
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
153
01:24Overview of Lipid Metabolism
4.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.7K